التفاصيل البيبلوغرافية
| العنوان: |
Venetoclax based combination therapy does not overcome poor outcomes in BTKi‐refractory mantle cell lymphoma: phase 2 trial of umbralisib, ublituximab, and venetoclax. |
| المؤلفون: |
Wallace, D. S., Rowland, C., Hill, B. T., Baran, A. M., Casulo, C., Reagan, P. M., Winter, A., Karmali, R., Winter, J. N., Gordon, L. I., Bui, A., Sportelli, P., Weiss, M. S., Miskin, H. P., Friedberg, J. W., Ma, S., Barr, P. M. |
| المصدر: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p484-486, 3p |
| مصطلحات موضوعية: |
MANTLE cell lymphoma, BRUTON tyrosine kinase, VENETOCLAX |
| مستخلص: |
Venetoclax based combination therapy does not overcome poor outcomes in BTKi-refractory mantle cell lymphoma: phase 2 trial of umbralisib, ublituximab, and venetoclax Cellular therapies should be prioritized for these patients for whom there is a critical ongoing need for novel treatment options. B Introduction: b Novel agents such as the Bruton's tyrosine kinase inhibitors (BTKi) have improved care for patients with mantle cell lymphoma (MCL), yet progression during BTKi is associated with poor outcomes. [Extracted from the article] |
|
Copyright of Hematological Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder